Stock Analiz

Royalty Pharma plc (RPRX) financials: revenue, earnings and cash flow

Fiscal 2018–2025 + TTM · from SEC filings · data as of November 13, 2026

Summary

Royalty Pharma’s revenue went from $1.8B in fiscal 2018 to $2.4B in fiscal 2025, growth of about 4.1% a year.

Net income in fiscal 2025 was $771M, a net margin of 32.4%; the best year in this period was 2019 with $2.3B.

Over the twelve months to September 30, 2026, revenue was $2.6B and net income $672M.

Revenue, profit and cash flow by year

Revenue
2018: $1.8B20182019: $1.8B20192020: $2.1B20202021: $2.3B20212022: $2.2B20222023: $2.4B20232024: $2.3B20242025: $2.4B2025$2.4B
Net income
2018: $1.4B20182019: $2.3B20192020: $975M20202021: $620M20212022: $43M20222023: $1.1B20232024: $859M20242025: $771M2025$771M
EPS (diluted)
2020: $1.3220202021: $1.4920212022: $0.1020222023: $2.5320232024: $1.9120242025: $1.782025$1.78

Income statement

Fiscal yearTTM20252024202320222021202020192018
Revenue$2.6B$2.4B$2.3B$2.4B$2.2B$2.3B$2.1B$1.8B$1.8B
Gross profit—————————
Operating income$1.5B$1.6B$1.3B$1.5B$307M$1.4B$1.6B$2.6B$1.4B
Net income$672M$771M$859M$1.1B$43M$620M$975M$2.3B$1.4B
EPS (diluted)$1.53$1.78$1.91$2.53$0.10$1.49$1.32——
R&D$251M$452M$2M$52M$177M$200M$26M$83M$393M
Revenue growth—+5.1%−3.9%+5.2%−2.3%+7.9%+17.0%+1.1%—

Cash flow

Fiscal yearTTM20252024202320222021202020192018
Operating cash flow$3.0B$2.5B$2.8B$3.0B$2.1B$2.0B$2.0B$1.7B$1.6B
Capital spending—————————
Free cash flow$3.0B————————
Dividends paid$409M$378M$376M$358M$333M$285M$112M——
Buybacks$262M$1.2B$230M$305M$0$0$0$4M$0
Stock-based pay$460M$290M$2M$2M$2M$2M$5M$0$0

Balance sheet

Fiscal yearTTM20252024202320222021202020192018
Cash—$637M$987M$495M$1.7B$1.6B$1.1B$246M$1.9B
Debt—$9.0B$7.6B$6.1B$7.1B$7.1B$5.8B$6.2B—
Equity—$9.7B$10.3B$10.1B$9.5B$10.2B$9.9B$6.1B$4.6B
Total assets—$19.6B$18.2B$16.4B$16.8B$17.5B$16.0B$12.4B—
Shares (diluted)557M564M594M603M438M415M375M——

Margins and returns

Fiscal yearTTM20252024202320222021202020192018
Gross margin—————————
Operating margin57.1%65.6%57.1%63.4%13.7%62.5%75.2%144.6%76.0%
Net margin25.7%32.4%38.0%48.2%1.9%27.1%45.9%129.4%76.8%
FCF margin113.1%————————
ROIC—8.3%7.2%9.2%1.8%8.2%10.2%21.2%30.0%
ROE—7.9%8.3%11.2%0.4%6.0%9.8%38.2%30.3%

Frequently asked questions

What is Royalty Pharma’s annual revenue?

$2.4B in fiscal 2025 and $2.6B over the twelve months to September 30, 2026.

How much profit does Royalty Pharma make?

Net income was $771M in fiscal 2025 (net margin 32.4%).

Is Royalty Pharma’s revenue growing?

Yes: revenue rose 5.1% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.